blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3250590

EP3250590 - COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTI-SSEA4 ANTIBODY EFFICACY [Right-click to bookmark this link]
Former [2017/49]COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY
[2021/23]
StatusNo opposition filed within time limit
Status updated on  22.07.2022
Database last updated on 06.07.2024
FormerThe patent has been granted
Status updated on  13.08.2021
FormerGrant of patent is intended
Status updated on  06.06.2021
FormerExamination is in progress
Status updated on  13.08.2019
FormerRequest for examination was made
Status updated on  03.11.2017
FormerThe international publication has been made
Status updated on  29.06.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Academia Sinica
128, Academia Road, Section 2
Nankang, Taipei 115 / TW
[2017/49]
Inventor(s)01 / WONG, Chi-Huey
P.O. Box 8154
Rancho Santa Fe, CA 92067 / US
02 / WU, Chung-Yi
No. 78-1
Dongshi St.
Xizhi Dist.
221 New Taipei City / TW
03 / MA, Che
c/o Academia Sinica
128 Academia Road
Section 2
115 Taipei / TW
04 / WU, Han-Chung
c/o Academia Sinica
128 Academia Road
Section 2
115 Taipei / TW
 [2018/12]
Former [2017/49]01 / WONG, Chi-Huey
P.O. Box 8154
Rancho Santa Fe, CA 92067 / US
02 / WU, Chung-Yi
No. 87-1
Dongshi St.
Xizhi Dist.
221 New Taipei City / TW
03 / MA, Che
c/o Academia Sinica
128 Academia Road
Section 2
115 Taipei / TW
04 / WU, Han-Chung
c/o Academia Sinica
128 Academia Road
Section 2
115 Taipei / TW
Representative(s)Lavoix
Bayerstraße 83
80335 München / DE
[2021/37]
Former [2017/49]Lavoix
Bayerstrasse 83
80335 München / DE
Application number, filing date16744256.530.01.2016
[2017/49]
WO2016US15858
Priority number, dateUS201562110338P30.01.2015         Original published format: US 201562110338 P
US20151472329727.05.2015         Original published format: US201514723297
US20151479831213.07.2015         Original published format: US201514798312
[2017/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016123593
Date:04.08.2016
Language:EN
[2016/31]
Type: A1 Application with search report 
No.:EP3250590
Date:06.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 04.08.2016 takes the place of the publication of the European patent application.
[2017/49]
Type: B1 Patent specification 
No.:EP3250590
Date:15.09.2021
Language:EN
[2021/37]
Search report(s)International search report - published on:US04.08.2016
(Supplementary) European search report - dispatched on:EP28.09.2018
ClassificationIPC:C07K16/28, C07K16/30, C12P19/14, A61P35/00
[2021/25]
CPC:
C07K16/32 (EP,IL,KR); C07K16/18 (EP,CN,IL,KR); A61P35/00 (EP,CN);
C07K16/241 (EP,IL,KR); C07K16/2887 (EP,IL,KR); C07K16/3084 (EP);
C07K16/44 (CN); A61K2039/505 (EP,CN); C07K2317/24 (EP,CN,IL);
C07K2317/41 (EP,CN,IL,KR); C07K2317/56 (EP,CN,IL,KR); C07K2317/565 (CN);
C07K2317/622 (EP,CN,IL,KR); C07K2317/72 (EP,CN,IL,KR); C07K2317/732 (EP,CN,IL,KR);
C07K2317/734 (EP,CN,IL,KR); C07K2317/92 (EP,CN,IL,KR) (-)
Former IPC [2021/23]C07K16/18, C07K16/30, C12P19/14, A61P35/00
Former IPC [2017/49]C07K16/00, C07K16/28, C07K16/30, C07K16/24, C07K16/10, A61K39/42
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/49]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN IM ZUSAMMENHANG MIT UNIVERSELLEN GLYKOFORMEN FÜR ERHÖHTE ANTI-SSEA4 ANTIKÖRPEREFFIZIENZ[2021/23]
English:COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTI-SSEA4 ANTIBODY EFFICACY[2021/23]
French:COMPOSITIONS ET PROCÉDÉS CONCERNANT DES GLYCOFORMES UNIVERSELLES POUR UNE EFFICACITÉ D'ANTICORPS ANTI-SSEA4 AMÉLIORÉE[2021/23]
Former [2017/49]ZUSAMMENSETZUNGEN UND VERFAHREN IM ZUSAMMENHANG MIT UNIVERSELLEN GLYKOFORMEN FÜR ERHÖHTE ANTIKÖRPEREFFIZIENZ
Former [2017/49]COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY
Former [2017/49]COMPOSITIONS ET PROCÉDÉS CONCERNANT DES GLYCOFORMES UNIVERSELLES POUR UNE EFFICACITÉ D'ANTICORPS AMÉLIORÉE
Entry into regional phase29.08.2017National basic fee paid 
29.08.2017Search fee paid 
29.08.2017Designation fee(s) paid 
29.08.2017Examination fee paid 
Examination procedure29.08.2017Examination requested  [2017/49]
29.08.2017Date on which the examining division has become responsible
03.04.2019Amendment by applicant (claims and/or description)
19.08.2019Despatch of a communication from the examining division (Time limit: M04)
27.11.2019Reply to a communication from the examining division
18.02.2021Cancellation of oral proceeding that was planned for 05.05.2021
05.05.2021Cancellation of oral proceeding that was planned for 06.05.2021
05.05.2021Date of oral proceedings (cancelled)
06.05.2021Date of oral proceedings (cancelled)
07.06.2021Communication of intention to grant the patent
05.08.2021Fee for grant paid
05.08.2021Fee for publishing/printing paid
05.08.2021Receipt of the translation of the claim(s)
Opposition(s)16.06.2022No opposition filed within time limit [2022/34]
Fees paidRenewal fee
26.01.2018Renewal fee patent year 03
31.01.2019Renewal fee patent year 04
30.01.2020Renewal fee patent year 05
28.01.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.01.2016
AL15.09.2021
CY15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
MK15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
IE30.01.2022
LU30.01.2022
[2024/22]
Former [2024/20]HU30.01.2016
AL15.09.2021
CY15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
IE30.01.2022
LU30.01.2022
Former [2024/18]HU30.01.2016
AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
IE30.01.2022
LU30.01.2022
Former [2023/09]AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
IE30.01.2022
LU30.01.2022
Former [2022/46]AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
LU30.01.2022
Former [2022/39]AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
MC15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/36]AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SI15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/29]AL15.09.2021
EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/25]EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
SM15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/24]EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RO15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
BG15.12.2021
GR16.12.2021
IS15.01.2022
PT17.01.2022
Former [2022/23]EE15.09.2021
HR15.09.2021
LT15.09.2021
LV15.09.2021
PL15.09.2021
RS15.09.2021
SE15.09.2021
SK15.09.2021
BG15.12.2021
GR16.12.2021
PT17.01.2022
Former [2022/10]HR15.09.2021
LT15.09.2021
LV15.09.2021
RS15.09.2021
SE15.09.2021
BG15.12.2021
GR16.12.2021
Former [2022/09]LT15.09.2021
RS15.09.2021
SE15.09.2021
BG15.12.2021
Former [2022/08]LT15.09.2021
SE15.09.2021
BG15.12.2021
Documents cited:Search[Y]US2011263828  (WONG CHI-HUEY [US], et al) [Y] 1-19* paragraphs [0020] , [0021] , [0091] , [0092]; claim 6 *;
 [Y]WO2013120066  (UNIV MARYLAND [US]) [Y] 1-19 * figures 1,3a,5a,7,8 *;
 [Y]  - Y.-W. LOU ET AL, "Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20140203), vol. 111, no. 7, doi:10.1073/pnas.1400283111, ISSN 0027-8424, pages 2482 - 2487, XP055218264 [Y] 1-19 * figures 1,5 *

DOI:   http://dx.doi.org/10.1073/pnas.1400283111
 [Y]  - WEI HUANG ET AL, "Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, (20120716), vol. 134, no. 29, doi:10.1021/ja3051266, ISSN 0002-7863, pages 12308 - 12318, XP055425387 [Y] 1-19 * Schemes 1-3;; figure 1 *

DOI:   http://dx.doi.org/10.1021/ja3051266
International search[YA]US2006286637  (HAMILTON STEPHEN R [US]) [Y] 1, 2, 12, 19 * claim 1, para [0162], [0341], [0364], [0435], [0436] * [A] 31-11, 13-18;
 [A]WO2008133857  (SCHERING CORP [US], et al) [A] 8-11, 13/(10, 11), (14-18)/13/(10, 11)* Claim 5; SEQ ID NO 12, 98.6% identity to SEQ ID NO:203 *;
 [A]WO2011074621  (MEDICAL & BIOL LAB CO LTD [JP], et al) [A] 8-11, 13/(10, 11), (14-18)/13/(10, 11) * Claim 2; SEQ ID NO 2, amino acids 20-141, 88.1% identity to SEQ ID NO:202 *;
 [A]US2013196356  (JACKSON GRAHAM STUART [GB], et al) [A] 3-7, 13/(6, 7), 14-18/13/(6, 7) * SEQ ID NO 11, amino acids 23-129, 93.3% identity to SEQ ID NO:148 *;
 [A]WO2014078373  (IOGENETICS LLC [US]) [A] 3-7, 13/(6, 7), 14-18/13/(6, 7) * Example 9; SEQ ID NO 276, amino acids 24-139, 91.2% identity to SEQ ID NO: 147 *;
 [YA]  - LOU et al., "Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers", Proc Natl Acad Sci USA, (20140000), vol. 111, no. 7, pages 2482 - 7, XP055218264 [Y] 1, 2, 12, 19 * ; Abstract, pg 2483, col 1 * [A] 3-11, 13-18

DOI:   http://dx.doi.org/10.1073/pnas.1400283111
 [YA]  - ZOU et al., "Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to Fcllla receptor", J Am Chem Soc., (20110000), vol. 133, no. 46, pages 18975 - 91, XP055061687 [Y] 1, 2, 12, 19 * ; Abstract, pg 24[according to the posted document], Fig 1 and its legend * [A] 31-11, 13-18

DOI:   http://dx.doi.org/10.1021/ja208390n
by applicantUS351
 US3773919
 USRE30985E
 US4419446
 US4560655
 US4601978
 WO8700195
 US4657866
 US4676980
 US4767704
 US4816567
 WO9003430
 US4927762
 US4965199
 US4975278
 WO9100360
 US5004697
 WO9110741
 WO9200373
 US5112596
 WO9209690
 US5122469
 WO9301161
 WO9306213
 WO9308829
 WO9316185
 US5264365
 US5268164
 WO9404690
 WO9411026
 WO9607754
 US5500362
 US5506206
 US5508192
 US5545807
 US5545806
 US5565332
 US5569825
 WO9634096
 WO9633735
 US5571894
 US5580717
 US5587458
 US5625126
 US5633425
 US5639635
 US5641870
 US5648237
 US5661016
 US5686416
 US5733743
 WO9824893
 US5821337
 US5840523
 US5869046
 US6004940
 US6027888
 US6083715
 US6265150
 US6329173
 US2002025313
 US2002038086
 US2002065259
 US2003073713
 US2003083299
 US2003104402
 US2003129186
 US2003162695
 WO03077945
 EP1391213
 US6703019
 US2004131692
 US2004204354
 US2005089473
 US2005124533
 US2009317837
 US2010136042
 US2014051127
 WO2015184009
    - LOU Y.-W. et al., PNAS, (20140000), vol. 111, no. 7, pages 2482 - 2487
    - CHEN, Y. et al., J. Mol Biol, (19990000), vol. 293, pages 865 - 881
    - ARIE et al., Mol. Microbiol., (20010000), vol. 39, pages 199 - 210
    - ORLANDIWARD et al., Nature, (19890000), vol. 341, pages 544 - 546
    - CHOTHIA et al., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - GALFRE et al., Methods Enzymol., (19810000), vol. 73, pages 563 - 681
    - WILEN et al., Tetrahedron, (19770000), vol. 33, page 2725
    - WILEN, Tables of Resolving Agents and Optical Resolutions, Univ. of Notre Dame Press, (19720000), page 268
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
    - MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, pages 6851 - 6855
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - PRESTA et al., Cancer Res., (19970000), vol. 57, pages 4593 - 4599
    - CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 628
    - KOHLER et al., Nature, (19750000), vol. 256, page 495
    - TOMLINSON et al., J. Mol. Biol., (19920000), vol. 227, pages 776 - 798
    - SIDHU et al., J. Mol. Biol., (20040000), vol. 340, no. 5, pages 1073 - 1093
    - FELLOUSE, Proc. Natl. Acad. Sci. USA, (20040000), vol. 101, no. 34, pages 12467 - 12472
    - LEE et al., J. Immunol. Methods, (20040000), vol. 284, no. 1-2, pages 119 - 132
    - JAKOBOVITS et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 7889 - 7893
    - JAKOBOVITS et al., Nature, (19930000), vol. 362, pages 255 - 258
    - BRUGGERMANN et al., Year in Immunol., (19930000), vol. 7, page 33
    - MARKS et al., Bio. Technology, (19920000), vol. 10, pages 779 - 783
    - LONBERG et al., Nature, (19940000), vol. 368, pages 812 - 813
    - FISHWILD et al., Nature Biotechnol., (19960000), vol. 14, pages 826 - 851
    - LONBERGHUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - VASWANIHAMILTON, Ann. Allergy, Asthma & Immunol., (19980000), vol. 1, pages 105 - 115
    - HARRIS, Biochem. Soc. Transactions, (19950000), vol. 23, pages 1035 - 1038
    - HURLEGROSS, Curr. Op. Biotech., (19940000), vol. 5, pages 428 - 433
    - HOOGENBOOM et al., J. Mol. Biol., (19910000), vol. 227, pages 381 - 597
    - BARBAS et al., Proc Nat. Acad. Sci. USA, (19940000), vol. 113, pages 3809 - 3813
    - CARTER et al., Bio/Technology, (19920000), vol. 10, pages 163 - 167
    - SCHIER et al., Gene, (19950000), vol. 169, pages 147 - 155
    - JACKSON et al., J. Immunol., (19950000), vol. 154, no. 7, pages 3310 - 2004
    - WINTER et al., Ann. Rev. Immunol., (19940000), vol. 12, pages 433 - 455
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - GRIFFITHS et al., EMBO J, (19930000), vol. 12, pages 725 - 734
    - HOOGENBOOM et al., Nucl. Acids Res., (19910000), vol. 19, pages 4133 - 4137
    - ORLANDI et al., Proc. Natl. Acad. Sci. (USA, (19890000), vol. 86, pages 5728 - 5732
    - JONES et al., Biotechnol., (19910000), vol. 9, pages 88 - 89
    - ORUM et al., Nucleic Acids Res., (19930000), vol. 21, pages 4491 - 4498
    - MATSUDA et al., Nature Genet., (19930000), vol. 3, pages 88 - 94
    - CARTER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 4285 - 3580
    - WILLIAMSWINTER, Eur. J. Immunol., (19930000), vol. 23, pages 1456 - 1461
    - HOGREFE et al., Gene, (19930000), vol. 128, pages 119 - 126
    - WATERHOUSE et al., Nucl. Acids Res., (19930000), vol. 21, pages 2265 - 2266
    - BARBAS et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, pages 7978 - 7982
    - EMBLETON et al., Nucl. Acids Res., (19920000), vol. 20, pages 3831 - 3837
    - BASS et al., Proteins, (19900000), vol. 8, pages 309 - 314
    - MARKS et al., Biotechnol., (19920000), vol. 10, pages 779 - 783
    - SKERRA et al., Curr. Opinion in Immunol., (19930000), vol. 5, pages 256 - 262
    - PLUCKTHUN, Immunol. Revs, (19920000), vol. 130, page 151
    - LEUNG et al., Technique, (19890000), vol. 1, pages 11 - 15
    - GUSS et al., EMBO J., (19860000), vol. 5, pages 15671575 - 103
    - KOZBOR, J. Immunol., (19840000), vol. 133, page 3001
    - BRODEUR et al., Monoclonal Antibody Production Techniques and Applications, American Society for Microbiology, (19870000), vol. 2, pages 1190 - 1219
    - BARNES et al., Anal. Biochem., (19800000), vol. 102, page 255
    - ENGELS et al., Agnew. Chem. Int. Ed. Engl., (19890000), vol. 28, pages 716 - 734
    - ABRAHMSEN et al., EMBO J., (19850000), vol. 4, page 3901
    - Methods in Enzymology, (19760000), vol. 44
    - RAVETCHKINET, Annu. Rev. Immunol, (19910000), vol. 1-3, pages 457 - 3242
    - SIEBENLIST et al., Cell, (19800000), vol. 20, page 269
    - YANSURA et al., METHODS: A Companion to Methods in Enzymol., (19920000), vol. 4, pages 151 - 158
    - SIMMONS et al., J. Immunol. Methods, (20020000), vol. 263, pages 133 - 147
    - CHEN et al., J Bio Chem, (19990000), vol. 274, pages 19601 - 19605
    - BOTHMANNPLUCKTHUN, J. Biol. Chem., (20000000), vol. 275, pages 17106 - 17113
    - HARA et al., Microbial Drug Resistance, (19960000), vol. 2, pages 63 - 72
    - LINDMARK et al., J. Immunol. Meth., (19830000), vol. 62, pages 1 - 13
    - REYES et al., Nature, (19820000), vol. 297, pages 598 - 601
    - GRAHAM et al., J. Gen Virol., (19770000), vol. 36, page 59
    - URLAUB et al., Proc. Natl. Acad. Sci. USA, (19800000), vol. 77, page 4216
    - MATHER, Biol. Reprod., (19800000), vol. 23, pages 243 - 251
    - MATHER et al., Annals N.Y. Acad. Sci., (19820000), vol. 383, pages 44 - 68
    - HAM et al., Meth. Enz., (19790000), vol. 58, page 44
    - CLYNES et al., PNAS (USA, (19980000), vol. 95, pages 652 - 656
    - GAZZANO-SANTORO et al., J. Immunol. Methods, (19960000), vol. 202, page 163
    - MORIMOTO et al., Journal of Biochemical and Biophysical Methods, (19920000), vol. 24, pages 107 - 117
    - BRENNAN et al., Science, (19850000), vol. 229, page 81
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - PLUCKTHUN, Immunol. Rev., (19920000), vol. 130, pages 151 - 188
    - MORRISON et al., Proc. Nat. Acad. Sci., (19840000), vol. 81, page 6851
    - NEUBERGER et al., Nature, (19840000), vol. 314, page 452
    - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623
    - CARTER et al., Proc. Natl. Acad Sci. USA, (19920000), vol. 89, page 4285
    - PRESTAETAL., J. Immnol., (19930000), vol. 151, page 2623
    - BRUGGERMANN et al., Year in Immuno., (19930000), vol. 7, page 33
    - WINTER, Annu. Rev. Immunol., (19940000), vol. 12, pages 433 - 455
    - MARKS et al., J. Mol Biol., (19910000), vol. 222, pages 581 - 597
    - WATERHOUSE et al., Nuc. Acids. Res., (19930000), vol. 21, pages 2265 - 2266
    - LIU et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 8618 - 8623
    - SYRIGOSEPENETOS, Anticancer Research, (19990000), vol. 19, pages 605 - 614
    - JONES et al., Biotechnol, (19910000), vol. 9, pages 88 - 89
    - MARKS et al., Biotechnol, (19920000), vol. 10, pages 779 - 783
    - YANSURA et al., METHODS: A Companion to Methods in Enzymol, (19920000), vol. 4, pages 151 - 158
    - GRAHAM et al., J. Gen Virol, (19770000), vol. 36, page 59
    - BOERNER et al., J. Immunol., (19910000), vol. 147, page 60
    - MILSTEINCUELLO, Nature, (19830000), vol. 305, page 537
    - TRAUNECKER et al., EMBO J., (19910000), vol. 10, page 3655
    - SURESH et al., Methods in Enzymology, (19860000), vol. 121, page 210
    - SHALABY et al., J. Exp. Med., (19920000), vol. 175, pages 217 - 225
    - KOSTELNY et al., J. Immunol., (19920000), vol. 148, no. 5, pages 1547 - 1553
    - GRUBER et al., J. Immunol., (19940000), vol. 152, page 5368
    - CUNNINGHAMWELLS, Science, (19890000), vol. 244, pages 1081 - 1085
    - A. L. LEHNINGER, Biochemistry, Worth Publishers, (19750000), pages 73 - 75
    - NICULESCU-DUVAZSPRINGER, Adv. Drg Del. Rev., (19970000), vol. 26, pages 151 - 172
    - BALDWIN et al., Lancet, (19860315), pages 603 - 05
    - THORPE et al., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506
    - ROWLAND et al., Cancer Immunol. Immunother., (19860000), vol. 21, pages 183 - 87
    - MANDLER et al., Jour. of the Nat. Cancer Inst., (20000000), vol. 92, no. 19, pages 1573 - 1581
    - MANDLER et al., Bioorganic & Med. Chem. Letters, (20000000), vol. 10, pages 1025 - 1028
    - MANDLER et al., Bioconjugate Chem., (20020000), vol. 13, pages 786 - 791
    - LODE et al., Cancer Res., (19980000), vol. 58, page 2928
    - HINMAN et al., Cancer Res., (19930000), vol. 53, pages 3336 - 3342
    - KAM et al., Proc. Natl. Acad. Sci., (20050000), vol. 102, pages 11600 - 11605
    - MARASCO, Gene Therapy, (19970000), vol. 4, pages 11 - 15
    - KONTERMANN, Methods, (20040000), vol. 34, pages 163 - 170
    - CHEN et al., Proc. Natl. Acad. Sci. USA, (19990000), vol. 96, pages 4325 - 4329
    - PAPANASTASSIOU et al., Gene Therapy, (20020000), vol. 9, pages 398 - 406
    - BOBO et al., Proc. Natl. Acad. Sci. USA, (19940000), vol. 91, pages 2076 - 2080
    - GILL et al., Nature Med., (20030000), vol. 9, pages 589 - 595
    - Peptide and Protein Drug Delivery, pages 247 - 301
    - A. Adv. Drug Delivery Rev, Marcel Dekker, Inc., (19910000), vol. 10, pages 29 - 90
    - LOBUGLIO, A.F.WHEELER, R.H.TRANG, J.HAYNES, A.ROGERS, K.HARVEY, E.B.SUN, L.GHRAYEB, J.KHAZAELI, M.B., "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response", Proc Natl Acad Sci USA, (19890000), vol. 86, doi:10.1073/pnas.86.11.4220, pages 4220 - 4224, XP002100301

DOI:   http://dx.doi.org/10.1073/pnas.86.11.4220
    - ROGUSKA, M.A.PEDERSEN, J.T.KEDDY, C.A.HENRY, A.H.SEARLE, S.J.LAMBERT, J.M.GOLDMACHER, V.S.BLATTLER, W.A.REES, A.R.GUILD, B.C., "Humanization of murine monoclonal antibodies through variable domain resurfacing", Proc Natl Acad Sci U S A, (19940000), vol. 91, doi:10.1073/pnas.91.3.969, pages 969 - 973, XP002271704

DOI:   http://dx.doi.org/10.1073/pnas.91.3.969
    - LU, R.-M.CHANG, Y.-L.CHEN, M.-S.WU, H.-C., "Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery", Biomaterials, (20110000), vol. 32, pages 3265 - 3274
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.